Study of the KPCXM18 Injection for Treatment of Acute Ischemic Stroke

A phase 2 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 240 participants.

Also called NCT05745311

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 240 participants (planned count) (from the registry)
Sponsor
Kunming Pharmaceuticals, Inc. (from the registry)
Registry
  • NCT NCT05745311
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Not reported
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT05745311. Randomized; triple masking; primary purpose treatment. Start 2023-03-01 (anticipated); primary completion 2024-05-01 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Study of the KPCXM18 Injection for Treatment of Acute Ischemic Stroke
Condition
Acute Ischemic Stroke
Intervention (Drug)
The KPCXM18 injection
Intervention (Drug)
Placebo
Lead sponsor
Kunming Pharmaceuticals, Inc. (class: industry)

Record details

Record id
cardio:ct-nct05745311
Content hash
287d374e48998ce2bd51405e4c5b66e247ffb5a2b146d58bae8704235a441009